21b172a2-72ce-4cfc-b021-cf8c36359feb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 47.8576317590691
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- APICAL_SURFACE+0.300
- G2M_CHECKPOINT+0.290
- ANGIOGENESIS+0.260
- MITOTIC_SPINDLE+0.260
- E2F_TARGETS+0.210
- TNFA_SIGNALING_VIA_NFKB+0.200
- WNT_BETA_CATENIN_SIGNALING+0.170
- TGF_BETA_SIGNALING+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.470
- OXIDATIVE_PHOSPHORYLATION-0.430
- FATTY_ACID_METABOLISM-0.370
- ALLOGRAFT_REJECTION-0.310
- ADIPOGENESIS-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- PANCREAS_BETA_CELLS-0.220
- COMPLEMENT-0.210
- DNA_REPAIR-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.783 |
| 2 | TCGA-F7-8298-01A-11R-2403-07 | — | — | 0.782 |
| 3 | 4b3022ba-0232-493c-b3fc-2447e8cf7113 | — | — | 0.769 |
| 4 | e040e6c8-34e5-44fb-a6f3-c247009fccfc | — | — | 0.762 |
| 5 | C3N-03662 | — | cohortSQ2 | 0.749 |
| 6 | SRR8518404 | — | D | 0.744 |
| 7 | TCGA-A7-A0DA-01A-31R-A115-07 | — | E | 0.743 |
| 8 | SRR8518444 | — | D | 0.738 |
| 9 | 50d521bc-fb39-4811-9126-09f092623809 | — | — | 0.735 |
| 10 | SRR23303761 | — | — | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |